Fundraising Fox

CoRegen

Aspen, US · Founded 2022 · Delaware corporation

Biotech

Founders & leadership

CC
Clifford C. Dasco, M.D.Chief Medical Officer of the Issuer
SC
Shawn C. TomaselloChief Executive Officer of the Issuer
JC
John C. Thomas, Jr.Chief Financial Officer and Secretary of the Issuer
DL
David Lonard, PhDChief Science Officer of the Issuer
SG
Steve GorlinNamed on SEC filing
BW
Bert W. O'MalleyNamed on SEC filing
BW
Bert W. O'Malley, M.D.Named on SEC filing
DM
David M. Cornell, IINamed on SEC filing

Board

EJ
Edward J. Benz, Jr.Board director
LF
Lee Fleisher, M.D.Board director
WH
William Haseltine, PhD.Board director
JW
Jonathan W. SimonsBoard director

Reported raises · per SEC filings

Form D private placements

$134.3M disclosed across 6 rounds · 2022–2025

▶$13.5MraisedFeb 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan W. SimonsDirector
  • Steve GorlinExecutive Officer, Director
  • Bert W. O'MalleyDirector
  • Suneet VarmaDirector
  • William Haseltine, PhD.Director
  • Sonja NelsonExecutive Officer
  • Sonal GuptaExecutive Officer
  • Lee FleisherDirector
  • Edward J. Benz, Jr.Director
  • Peter GelinasExecutive Officer
Offering amount
$13.5M
Amount sold
$13.5M
Sales commissions
$540K
Placement agents
Terrance Joseph Philips, Marc Christopher Rucinski
First sale
Oct 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$62.6MraisedMay 2025 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lee Fleisher, M.D.Director
  • John Thomas, Jr.Executive Officer
  • Jonathan W. SimonsDirector
  • William Haseltine, PhD.Director
  • Edward J. Benz, Jr.Director
  • David Lonard, PhDExecutive Officer
  • Suneet VarmaDirector
  • Steve GorlinExecutive Officer, Director
  • Clifford C. Dasco, M.D.Executive Officer, Director
  • Bert W. O'MalleyDirector
Offering amount
$62.6M
Amount sold
$62.6M
Minimum investment
$25K
Sales commissions
$4.1M
Placement agents
Elena Ulansky, Jeff Robert Swarz
First sale
Apr 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.8MraisedFeb 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shawn C. TomaselloExecutive Officer, Director
  • Steve GorlinDirector
  • Lee Fleisher, M.D.Director
  • John C. Thomas, Jr.Executive Officer
  • William Haseltine, PhD.Director
  • Bert W. O'MalleyDirector
  • Edward J. Benz, Jr.Director
  • Jonathan W. SimonsDirector
  • Clifford C. Dasco, M.D.Executive Officer, Director
  • David Lonard, PhDExecutive Officer
Offering amount
$20.8M
Amount sold
$20.8M
Minimum investment
$25K
Sales commissions
$1.4M
Placement agents
Jeff Robert Swarz, Elena Ulansky
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedFeb 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward J. Benz, Jr.Director
  • Lee Fleisher, M.D.Director
  • William Haseltine, PhD.Director
  • Steve GorlinDirector
  • Bert W. O'MalleyDirector
  • Clifford C. Dasco, M.D.Executive Officer, Director
  • Jonathan W. SimonsDirector
  • Shawn C. TomaselloExecutive Officer, Director
  • John C. Thomas, Jr.Executive Officer
  • David Lonard, PhDExecutive Officer
Offering amount
$10M
Amount sold
$10M
Minimum investment
$25K
Sales commissions
$700K
Placement agents
Jeff Robert Swarz, Elena Ulansky
First sale
Feb 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.9MraisedMar 2024 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David M. Cornell, IIDirector
  • Bert W. O'MalleyDirector
  • Steve GorlinExecutive Officer, Director
  • Edward J. Benz, Jr.Director
  • John C. Thomas, Jr.Executive Officer
  • Clifford C. Dasco, M.D.Director
  • David Lonard, PhDExecutive Officer
Offering amount
$12.9M
Amount sold
$12.9M
Minimum investment
$25K
Sales commissions
$84K
Proceeds to insiders
$1M
Placement agents
Elena Ulansky, Jeff Robert Swarz
First sale
Aug 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.5MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward J. Benz, Jr.Director
  • Bert W. O'Malley, M.D.Director
  • John C. Thomas, Jr.Executive Officer
  • Clifford C. Dasco, M.D.Director
  • David M. Cornell, IIDirector
  • Steve GorlinExecutive Officer, Director
  • David Lonard, PhDExecutive Officer
Amount sold
$14.5M
Minimum investment
$14.5M
First sale
Feb 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

CoRegen Inc. Raises $13 | Signalbasetrysignalbase.com · Mar 2026Sell or Invest in CoRegen Stock Pre-IPOnasdaqprivatemarket.com · Jul 2025CoRegen, Inc. Closes More Than $93 Million Financing - BioSpacebiospace.com · Jul 2025CoRegen Secures $93 Million to Advance Novel Treg Cell Therapies into Clinic | PackGene Biotechpackgene.com · Jul 2025CoRegen secures $93.3M to advance cancer therapy from Baylor College of Medicine researcher - Houston Business Journalbizjournals.com · Jul 2025CoRegen Raises Over $93M in Fundingfinsmes.com · Jul 2025

Frequently asked questions

How much funding has CoRegen raised?
CoRegen has disclosed $134.3M raised across 6 rounds.
Where is CoRegen headquartered?
CoRegen is headquartered in Aspen, US.